Kevin Wei
Rheumatology · Boston, MANPI 1114212263
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,909 of the $21,188 with a category attached, or 75.1%. 5 manufacturers reported payments, led by Merck at 43.5% of the total. Reporting peaked in 2023 at $8,717 and has fallen 84.1% since, to $1,389 in 2025.
Across 24 payments — averaging $882.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$9K
- Gilead$7K
- Pfizer$2K
- Amgen$2K
- Bristol Myers Squibb$428
Across 4 payments — averaging $187,822 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$400K
- Gilead$351K
What the payments were for
- Consulting fees$15,90975%
- Speaking & faculty fees$2,95014%
- Travel & lodging$7814%
- Food & beverage$1,5487%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 15 | $9,207 |
| Gilead | 3 | $7,214 |
| Pfizer | 4 | $2,339 |
| Amgen | 1 | $2,000 |
| Bristol Myers Squibb | 1 | $428 |
How this compares
$21,188 in reported general payments places this provider in the 80th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $95,996 |
| MethotrexateMethotrexate Sodium | 18 | $927 |
| Gabapentin | 15 | $515 |
| Hydroxychloroquine Sulfate | 12 | $371 |
| Prednisone | 20 | $249 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tanya LaidlawBoston$244K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.